New treatment options for relapsing-remitting multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Natalizumab: A new treatment for relapsing remitting multiple sclerosis
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to alpha(4)beta(1)-integrin. In a Phase 3 trial, 2 years of natalizumab monotherapy reduced the mean annualized relapse rate (ARR) by 68% compared with placebo (p < 0.001) and the risk of sustained disability progression was reduced by 42% in the nataliz...
متن کاملCladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
INTRODUCTION Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine ta...
متن کاملOral laquinimod for treatment of relapsing-remitting multiple sclerosis.
Laquinimod is a novel oral immunomodulator developed as a disease-modifying drug for relapsing-remitting multiple sclerosis (RRMS). This molecule was developed following a structure-activity relationship program with Roquinimex. Laquinimod has shown a marked beneficial effect in acute, chronic progressive and chronic relapsing models of experimental autoimmune encephalomyelitis. It shifts the c...
متن کاملAlemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for...
متن کاملAlemtuzumab for relapsing-remitting multiple sclerosis.
In the past 10 years, the treatment options for patients with relapsing-remitting multiple sclerosis (RRMS) underwent some major changes. After relying on injectable interferon-beta preparations for quite some time, the advent of the first monoclonal antibody, natalizumab, followed by the first oral drug, fingolimod, improved the outcome of these patients and the possibilities to treat them mor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Praktické lékárenství
سال: 2019
ISSN: 1801-2434,1803-5329
DOI: 10.36290/lek.2019.013